Cellectar Biosciences Inc (CLRB)

[staccani]

For sure they will present ph2 interim results on the 28th.

[Crusader]

I hope to post CLRB NEWS...

7 or 8 days from now, regarding Phase 3 Clinical Trial data on CLR 131 in relapsed/refractory DLBCL.

[Crusader]

Staccani: there was this:

FLORHAM PARK, N.J., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences (CLRB), Inc. , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced Mr. Jarrod Longcor, chief business officer of Cellectar presented data from Cohort 6 of its Phase 1 dose escalation study of CLR 131 in relapsed or refractory multiple myeloma (R/R MM), in a late breaker poster at the 17th International Myeloma Workshop being held in Boston, MA from September 12-15, 2019.

The poster, entitled: “CLR 131 Demonstrates High Rate of Activity in a Phase 1, Dose Escalation Study in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)” highlights data from 4 subjects in Cohort 6 who received a fractionated dose of 37.5 mCi/m2. Subjects in this cohort achieved a 50% overall response rate, with two subjects achieving a partial response and two subjects achieving minimal responses (39% and 48% reduction in M protein). CLR 131 was deemed safe and tolerated in all subjects with cytopenias being the only reported treatment emergent adverse events of grade 3 or higher. The majority (75%) of the subjects had high risk cytogenetics where median bone marrow plasma cell involvement was 25%. Patients’ median age was 72.5 and averaged 5 prior systemic therapies, with one patient being dual class refractory, one being quad-refractory, and two being penta-refractory.

The Phase 1 study employs the International Myeloma Working Group (IMWG) criteria for measuring responses. The IMWG defines a partial response as a 50% reduction in the marker of disease and a minimal response as a 25% to 49.9% reduction.

“Cohort 6’s overall response rate of 50% with 100% disease control in highly chemo-refractory elderly patients highlights CLR 131’s potential as a first-in-class targeted radiotherapeutic for relapsed or refractory multiple myeloma. We saw an encouraging dose response compared to prior cohorts and CLR 131 continues to demonstrate a favorable safety profile,” said James Caruso, president and CEO of Cellectar. “We have progressed to a higher 40 mCi/m2 fractionated dose Cohort 7, with data expected in Q4 2019. Additionally, based on the positive results from Cohort 6, we are now allowed to use the 37.5 mCi/m2 dosing level in our ongoing Phase 2 (CLOVER-1) study evaluating CLR 131 in patients with relapsed/refractory (R/R) B-cell malignancies and expect data from the Phase 2 trial in Q4 2019.”

https://ih.advfn.com/stock-market/NASDAQ/cellectar-biosciences-CLRB/stock-news/80737952/current-report-filing-8-k#TV529504_EX99-1_HTM

[staccani]

Any info on what was presented yesterday at the MM workshop?

[Crusader]

Yes, it is hard betting against The House.

I have sell orders GTC in place just incase the next spike is ridiculous.

Good luck.

[Rymankoly]

Hard to say ....
Not really watching it those days, but I think the cycle will continue (price jump and raise money then price fall)

If i was holding, I would have sell 30-50% on any spike and buy back later if I would like to keep it.
I think there are better plays out there

[Crusader]

17th IMW workshop in Boston for tomorrow has published abstracts:

Poster SP305 by CLRB, at page 555 (public document linked below):


“...Conclusions: CLR 131 represents a first in class targeted radiotherapeutic for RRMM. These data suggest that RRMM including high-risk patients can experience meaningful clinical benefit from treatment with CLR 131 with an acceptable and expected safety profile in the fractionated dose cohorts. Based upon this encouraging activity in late line RRMM patients, this dose of CLR 131 is being Standardized...”


https://files.aievolution.com/imw1901/docs/17th_IMW_Abstract_Book_FINAL_V2.pdf

[Crusader]

Rymankoly: Remember this reply

To your May 2019 post:

Crusader:

“Yes, typical, sell the CLRB news,

LEARNED BEHAVIOR UNTIL THE BEAR TRAP IS SPRUNG,

LATER THIS YEAR...October??? “.


You also correctly wrote in another post around that same time: “People are not learning.”



WELL NOW, IT IS ALMOST OCTOBER! Will things ever change? Tomorrow groundhog day or not?

[Crusader]

Today’s strong price action (again)

I think is is because of tomorrow’s planned data release:

International Myeloma Workshop, Boston (4 days). Cellectar Biosciences (NASDAQ:CLRB): Phase 1 data on CLR 131 in MM.

THESE CONFERENCE PRESENTATIONS USUALLY RESULT IN A DOWNWARD CORRECTION OF ALMOST 3%, BUT MAYBE THIS TIME WILL BE DIFFERENT WITH HARD CLINICAL TRIAL NUMBERS RELEASED AND NOT JUST FLUFF!

[Crusader]

Solid price action today,

it convinced me to buy six figures more common shares.

Perhaps we expect too much/ too soon from the upcoming conference presentation by CLRB.

Time will tell in a week or so.

[Crusader]

Sure enough, they are selling this kind of news,

[Crusader]

[Crusader]

Load the truck while you

can afford to do it!!!

Of course “they” will sell this news, but not the FDA news in a couple months or sooner.

It will not just be clinical trial news. Buy-out news seems likely...try selling that news...NOT!

[TeddyCaswell]

Loading Now lets see 5$

[Crusader]

SEC filing on new 9% owner of CLRB stock:

https://ih.advfn.com/stock-market/NASDAQ/cellectar-biosciences-inc-CLRB/stock-news/80236068/statement-of-ownership-sc-13g

Text from link:


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. )*

Cellectar Biosciences, Inc.
(Name of Issuer)

Common Stock, par value $0.00001 per share
(Title of Class of Securities)

15117F500
(CUSIP Number)

June 20, 2019
(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed.
?
Rule 13d-1(b)
?
Rule 13d-1(c)
?
Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 15117F500
SCHEDULE 13G
Page 2 of 8


1
NAME OF REPORTING PERSON OR
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

North Sound Management, Inc.

2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP


(a) o
(b) o
3
SEC USE ONLY



4
CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF
SHARES
BENEFICIALLY OWNED
BY EACH REPORTING
PERSON
WITH
5
SOLE VOTING POWER

850,000
6
SHARED VOTING POWER

0
7
SOLE DISPOSITIVE POWER

850,000
8
SHARED DISPOSITIVE POWER

0
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

850,000

10
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES


o
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

9.0%

12
TYPE OF REPORTING PERSON

CO



CUSIP No. 15117F500
SCHEDULE 13G
Page 3 of 8


1
NAME OF REPORTING PERSON OR
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Brian Miller

2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP


(a) o
(b) o
3
SEC USE ONLY



4
CITIZENSHIP OR PLACE OF ORGANIZATION

United States of America

NUMBER OF
SHARES
BENEFICIALLY OWNED
BY EACH REPORTING
PERSON
WITH
5
SOLE VOTING POWER

850,000
6
SHARED VOTING POWER

0
7
SOLE DISPOSITIVE POWER

850,000
8
SHARED DISPOSITIVE POWER

0
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

850,000

10
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES


o
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

9.0%

12
TYPE OF REPORTING PERSON

IN


CUSIP No. 15117F500
SCHEDULE 13G
Page 4 of 8


1
NAME OF REPORTING PERSON OR
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

North Sound Trading, LP

2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP


(a) o
(b) o
3
SEC USE ONLY



4
CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF
SHARES
BENEFICIALLY OWNED
BY EACH REPORTING
PERSON
WITH
5
SOLE VOTING POWER

850,000
6
SHARED VOTING POWER

0
7
SOLE DISPOSITIVE POWER

850,000
8
SHARED DISPOSITIVE POWER

0
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

850,000

10
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES


o
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

9.0%

12
TYPE OF REPORTING PERSON

PN


CUSIP No. 15117F500
SCHEDULE 13G
Page 5 of 8


ITEM 1.
(a)
Name of Issuer:


Cellectar Biosciences, Inc. (the “Issuer”)


(b)
Address of Issuer’s Principal Executive Offices:

100 Campus Drive
Florham Park, New Jersey 07932

ITEM 2.
(a)
Name of Person Filing:


This statement is being filed on behalf of each of the following persons (each, a “Reporting Person” and, collectively, the “Reporting Persons”):


(1) North Sound Management, Inc.
(2) Brian Miller
(3) North Sound Trading, LP


Mr. Miller is the sole shareholder of North Sound Management, Inc., the general partner of North Sound Trading, LP.


(b)
Address of Principal Business Office, or if none, Residence:

The principal business address for each of the Reporting Persons is:

c/o North Sound Management, Inc.
115 East Putnam Avenue
Greenwich, CT 06830


(c)
Citizenship:


See row 4 of the cover page of each Reporting Person.


(d)
Title of Class of Securities:


See cover page.


(e)
CUSIP Number:

See cover page.

ITEM 3.
IF THIS STATEMENT IS FILED PURSUANT TO §240.13D-1(B) OR 240.13D-2(B) OR (C), CHECK WHETHER THE PERSON FILING IS A:


Not applicable.

ITEM 4.
OWNERSHIP.


(a)
Amount beneficially owned:

See row 9 of the cover page of each Reporting Person


(b)
Percent of class:

Each of the Reporting Persons may be deemed to be the beneficial owner of 9.0% of the outstanding shares of the Issuer’s common stock, par value $0.00001 per share (“Common Stock”).

The calculations of beneficial ownership percentage is based on 9,396,036 shares of Common Stock issued and outstanding as of May 30, 2019, as reported in the Issuer’s Form S-1 filed with the Securities and Exchange Commission on May 31, 2019.

[Crusader]

SEC: Institution just bought 9% of CLRB,

and it becomes 2nd largest investor at low price per share.

IT MAKES ONE WONDER WHAT THEY KNOW,

https://fintel.io/so/us/clrb

[Sunofwolf]

stock took a dive in after market! I don't care what this company claims=it doesn't make anything but loses money but spends money on a fancy office for the CEO on the investors dime. These studies have like two patient's. a sugar pill would get great results too!

[Crusader]

3 BAGGER in 90 days?

Cellectar Expands Third Cohort of its Phase 2
CLOVER-1 Study of CLR 131
Response rate exceeded pre-specified value; top-line results of Phase 2 study expected in
2019

FLORHAM PARK, N.J., May 21, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB),


clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for
the treatment of cancer, today announced that initial results from the third cohort of its ongoing Phase 2 CLOVER-1
study of CLR 131 have exceeded its pre-specified performance criteria.

As a result, the Company will expand the
number of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), lymphoplasmacytic lymphoma
(LPL) and marginal zone lymphoma (MZL) patients it will enroll in the cohort. The company continues to expect to
report top-line data from the Phase 2 CLOVER-1 study in 2019.
“Initial results from our Phase 2 CLOVER-1 study have been very encouraging and we are excited to be able to
expand patient enrollment,” stated James Caruso, president and chief executive officer of Cellectar Biosciences.
“With the proceeds from the recently announced financing, we now have a cash runway through the conclusion of
2020, allowing us to deliver key anticipated milestones for CLR 131 in three ongoing clinical trials, including the
conclusion of and top-line data from our ongoing Phase 2 CLOVER-1 trial in relapse/refractory select B-Cell
malignancies, our ongoing Phase 1 dose-escalating trial in relapsed/refractory multiple myeloma, and our recently
initiated Phase 1 dose-escalating trial in children and adolescents with select solid tumors, lymphoma, and malignant
brain tumors.”

The company previously announced positive top-line data from two cohorts of the ongoing Phase 2 CLOVER-1 trial.
In the relapsed/refractory diffuse large b-cell lymphoma (DLBCL) cohort, CLR 131 demonstrated a 33% overall
response rate as a fourth line systemic treatment; and in the relapsed/refractory multiple myeloma (MM) cohort, CLR
131 demonstrated a 30% overall response rate as the seventh line systemic treatment on average. Patients in both
of these cohorts received a single 30-minute infusion of 25mCi/m2 of CLR 131. The company continues to enroll
patients in both cohorts and patients are now receiving 37.575mCi/m2 of CLR 131 administered in two 30-minute
infusions of 18.75mCi/m2.

The company expects to announce top-line data from the Phase 2 CLOVER-1 trial in
2019.

About the Phase 2 CLOVER-1 Trial
CLOVER-1 is a Phase 2 study of CLR 131 being conducted in approximately 10 leading cancer centers in the
United States in patients with relapsed or refractory B-cell hematologic cancers. The hematologic cancers being
studied in the trial include multiple myeloma (MM), chronic lymphocytic leukemia/small lymphocytic lymphoma
(CLL/SLL), lymphoplasmacytic lymphoma (LPL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), and
diffuse large B-cell lymphoma (DLBCL).
The study's primary endpoint is clinical benefit response (CBR), with additional endpoints of overall response rate
(ORR), progression free survival (PFS), median overall survival (OS) and other markers of efficacy following a
fractionated dose of 37.575mCi/m2 of CLR 131 administered in two 30-minute infusions of 18.75mCi/m2 of CLR 131
administered on day 1 and day 8, with the option for a second dose cycle approximately 75-180 days later.
In addition to receiving the two fractionated doses of CLR 131, MM patients will receive 40 mg oral dexamethasone
weekly for up to 12 weeks. Efficacy responses will be determined by the latest International Multiple Myeloma
Working Group criteria. Efficacy for all lymphoma patients will be determined according to Lugano criteria. Cellectar
was awarded approximately $2 million in non-dilutive grant funding from the National Cancer Institute to help fund
the trial. More information about the trial, including eligibility requirements, can be found at www.clinicaltrials.gov,
reference NCT02952508.
About CLR 131
CLR 131 is a small-molecule, cancer-targeting radiotherapeutic PDC designed to deliver cytotoxic radiation directly
and selectively to cancer cells and cancer stem cells. CLR 131 is the company’s lead therapeutic PDC product
candidate and is currently being evaluated in both Phase 2 and Phase 1 clinical studies. In December 2014, the
FDA granted orphan drug designation for CLR 131 for the treatment of multiple myeloma. In 2018, the FDA granted
orphan drug and rare pediatric disease designations for CLR 131 for the treatment of neuroblastoma,
rhabdomyosarcoma, Ewing’s sarcoma and osteosarcoma. In addition to the ongoing Phase 1 dose-escalation study
and the Phase 2 CLOVER-1 trial, the company recently initiated a Phase 1 open-label, dose-escalating study in
pediatric solid tumors and lymphoma to evaluate the safety and tolerability of a single intravenous administration of
CLR 131 in up to 30 children and adolescents with cancers including neuroblastoma, sarcomas, lymphomas
(including Hodgkin’s lymphoma) and malignant brain tumors

[Sunofwolf]

Hit hard today-can't find out what this news release is about, can't be good news. this is a fake company, only money it makes is from investors, will never have anything that will make a penny in profits.

[whytestocks]

News: $CLRB NetworkNewsBreaks - Cellectar Biosciences, Inc. (NASDAQ: CLRB) Secures $10M Through RDO Sale, Private Placement

Clinical stage biopharmaceutical company Cellectar Biosciences (NASDAQ: CLRB) has closed a registered direct offering sale of 1,982,000 common shares and concurrent private placement of 2,018,000 common shares with institutional investors. In conjunction with the offerings, the company issued ...

In case you are interested https://marketwirenews.com/news-releases/networknewsbreaks-cellectar-biosciences-inc-nasdaq-clrb-secures-10m-through-rdo-sale-private-placement-8242530.html

[Sunofwolf]

Looks like someone bought 600,000 shares more than the whole management owns must be a sucker to buy into a company that has made anything of value in years.

[Optionsrbest4u]

100% disease control rate...today announces expansion of cohort 3 in P2 Clover-1 study - up 8% pre-market.

[Sunofwolf]

This company is worthless, their tech is outdated and they develop nothing, the CEO is just a leach sitting on a fancy couch and office in NJ laughing at the fools that invest here. All the original founders are long gone. Notice the directors themselves invest nothing but give themselves stock options and free stock.

[Sunofwolf]

fake company-they have not developed anything but a leather couch in NJ fancy office for the CEO! Never made 2 cents!

[Sunofwolf]

dumping more stock on investors

[Sunofwolf]

Pump and dump LOL! Actually might be a good price here!

[Crusader]

Yes, typical, sell the CLRB news,

LEARNED BEHAVIOR UNTIL THE BEAR TRAP IS SPRUNG,

LATER THIS YEAR...October???

[Rymankoly]

Same as previous runs...
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=142248871

People are not learning

[whytestocks]

News: $CLRB Cellectar Biosciences Announces $10.0 Million Financing

FLORHAM PARK, N.J., May 16, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that it has entered into definitive a...

Got this from https://marketwirenews.com/news-releases/cellectar-biosciences-announces-10-0-million-financing-8198734.html

[whytestocks]

News: $CLRB Global Medical Device Market Projected To Be $595 Billion By 2024

May 16, 2019 Palm Beach, FL –May 16, 2019 –  The initial diagnosis and the 2 nd opinions all show that the global medical device markets are projected to have a very healthy revenue prognosis through 2014.  In the 2018 edition of the EvaluateMedTech® ...

Got this from https://marketwirenews.com/news-releases/global-medical-device-market-projected-to-be-595-billion-by-2024-8198464.html

[ClayTrader]

* * $CLRB Video Chart 05-15-2019 * *

Link to Video - click here to watch the technical chart video

[Longer Than Most]

Nice news. $CLRB pullback but looks really good as a long term position

[Crusader]

Quick 50% retracement of gains,

while folks in NYC were out to lunch.

This will work for 4 or 5 more months, then spikes will become bear traps- not bull traps.

Happy ?? to learn long ago not to buy the spikes. Just buy the winners cheap & hold them close.

[Crusader]

It took 4 months, BUT:

See my January post #7829 linked above:

Where will we be in 4 more months? 6 months?

$6 pps?

[Crusader]

So true, whytestocks:

“...Thinly traded nano cap Cellectar Biosciences (CLRB +30.7%) is up on a robust 32x surge in volume in reaction to preliminary data from Cohort 6 in its Phase 1 study of CLR 131 in patients with relapsed/refractory multiple myeloma.

Results showed a 50% partial response rate, a 50% minimal response rate and a 100% disease control rate (responders + stable cancer).

The company has initiated a seventh cohort at a higher dose. Interim data should be available in Q4.

CLR 131 is a phospholipid ether-drug conjugate (PDC) that selectively delivers radiation to malignant cancer cells...” SA

[Crusader]

No wonder the FDA backs CLRB

with Fast Track Status to get CLR131 to market. It is MM patients last best chance to live.

I would pay $75,000 per infusion for it, in order to live 2 or 3 more years. A LOT MORE cures can be found in 2 or 3 years.

[Crusader]

Growth EXCEEDS share dilution,

...and EVERYBODY CAN WIN.

CLRB WILL BE A BLESSING to cancer patients and to investors.

Thank God!

[Crusader]

A NEW DAY FOR CLRB IS READY TO DAWN,

as sunofwolf’s negative BS slowly sets in the west, to be forgotton,

CLRB PROVES ITS FUTURE IN A NEW DAY OF HOPE IN TODAY’ S PR AND MANY MORE LIKE IT TO COME THIS YEAR.

As a MM patient, I applaud this biotech company and all it is doing to protract human lives !

A cure is a dream; an effective cancer management technology is reality. CLRB!

[whytestocks]

News: $CLRB CLR 131 Achieves 50% Overall Response Rate in Cohort 6 of Ongoing Phase 1 Study in Relapsed or Refractory Multiple Myeloma

Results demonstrated 50% partial response rate, 50% minimal response rate, and 100% disease control rate Independent Data Monitoring Committee determines dose to be safe and well tolerated and recommends study continue to Cohort 7 FLORHAM PARK, N.J., May 15, 2019 (GLOBE NEWSWIRE) -...

Find out more https://marketwirenews.com/news-releases/clr-131-achieves-50-overall-response-rate-in-cohort-6-of-ongoing-phase-1-study-in-relapsed-or-refractory-multiple-myeloma-8190654.html

[Crusader]

Fast Track Status for CLR131

from the FDA today for refractory MM?

That sets the table for the next spike over 2.75 not to retrace.

Share dilution by management sets the table for more depressing BS.

PLACE YOUR BETS

[whytestocks]

News: $CLRB Cellectar Reports First Quarter 2019 Financial Results and Provides a Corporate Update

Reported positive top-line results from relapsed/refractory multiple myeloma cohort in ongoing Phase 2 clinical study of CLR 131 Announced median overall survival rate of 22 months in Cohorts 1-4 in its ongoing Phase 1 clinical study of CLR 131 in relapsed/refractory multiple myeloma ...

Find out more https://marketwirenews.com/news-releases/cellectar-reports-first-quarter-2019-financial-results-and-provides-a-corporate-update-8122574.html

[Sunofwolf]

snake oil company! company in a briefcase-desk draw, no value at all.

[Sunofwolf]

reverse coming look at it tank, the company has done nothing for all the investor money except waste it on fancy perks for the CEO!

[Sunofwolf]

700,000 shares of dilution coming, Ya these jerk offs paying for extremely poor performance-Fraud!

[Longer Than Most]

$CLRB on watch

[Sunofwolf]

Down every day-now that the fake news is over!

[Sunofwolf]

CEO can't wait to dilute the stock again make your shares worthless!

[Sunofwolf]

Junky news 131 being made again-big deal for like ten people who are all ready walking dead people!

[Sunofwolf]

Never would have had this problem-If not for the incompetence of the CEO-they were making the drug themselves. This company is rubbish-they will never come up with anything but a fancy office paid for by investors-sukers!

[whytestocks]

News: $CLRB FDA Grants Exemption to Import Alert for Cellectar's CLR 131 in Pediatric and Adolescent Patients

FLORHAM PARK, N.J., March 19, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the U.S. Food and Drug Ad...

In case you are interested https://marketwirenews.com/news-releases/fda-grants-exemption-to-import-alert-for-cellectar-s-clr-131-in-pediatric-and-adolescent-patients-7855778.html